2954 related articles for article (PubMed ID: 33734299)
1. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial.
; Sadeghipour P; Talasaz AH; Rashidi F; Sharif-Kashani B; Beigmohammadi MT; Farrokhpour M; Sezavar SH; Payandemehr P; Dabbagh A; Moghadam KG; Jamalkhani S; Khalili H; Yadollahzadeh M; Riahi T; Rezaeifar P; Tahamtan O; Matin S; Abedini A; Lookzadeh S; Rahmani H; Zoghi E; Mohammadi K; Sadeghipour P; Abri H; Tabrizi S; Mousavian SM; Shahmirzaei S; Bakhshandeh H; Amin A; Rafiee F; Baghizadeh E; Mohebbi B; Parhizgar SE; Aliannejad R; Eslami V; Kashefizadeh A; Kakavand H; Hosseini SH; Shafaghi S; Ghazi SF; Najafi A; Jimenez D; Gupta A; Madhavan MV; Sethi SS; Parikh SA; Monreal M; Hadavand N; Hajighasemi A; Maleki M; Sadeghian S; Piazza G; Kirtane AJ; Van Tassell BW; Dobesh PP; Stone GW; Lip GYH; Krumholz HM; Goldhaber SZ; Bikdeli B
JAMA; 2021 Apr; 325(16):1620-1630. PubMed ID: 33734299
[TBL] [Abstract][Full Text] [Related]
2. Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial.
Bikdeli B; Talasaz AH; Rashidi F; Bakhshandeh H; Rafiee F; Rezaeifar P; Baghizadeh E; Matin S; Jamalkhani S; Tahamtan O; Sharif-Kashani B; Beigmohammadi MT; Farrokhpour M; Sezavar SH; Payandemehr P; Dabbagh A; Moghadam KG; Khalili H; Yadollahzadeh M; Riahi T; Abedini A; Lookzadeh S; Rahmani H; Zoghi E; Mohammadi K; Sadeghipour P; Abri H; Tabrizi S; Mousavian SM; Shahmirzaei S; Amin A; Mohebbi B; Parhizgar SE; Aliannejad R; Eslami V; Kashefizadeh A; Dobesh PP; Kakavand H; Hosseini SH; Shafaghi S; Ghazi SF; Najafi A; Jimenez D; Gupta A; Madhavan MV; Sethi SS; Parikh SA; Monreal M; Hadavand N; Hajighasemi A; Maleki M; Sadeghian S; Piazza G; Kirtane AJ; Van Tassell BW; Stone GW; Lip GYH; Krumholz HM; Goldhaber SZ; Sadeghipour P
Thromb Haemost; 2022 Jan; 122(1):131-141. PubMed ID: 33865239
[TBL] [Abstract][Full Text] [Related]
3. Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies.
Bikdeli B; Talasaz AH; Rashidi F; Sharif-Kashani B; Farrokhpour M; Bakhshandeh H; Sezavar H; Dabbagh A; Beigmohammadi MT; Payandemehr P; Yadollahzadeh M; Riahi T; Khalili H; Jamalkhani S; Rezaeifar P; Abedini A; Lookzadeh S; Shahmirzaei S; Tahamtan O; Matin S; Amin A; Parhizgar SE; Jimenez D; Gupta A; Madhavan MV; Parikh SA; Monreal M; Hadavand N; Hajighasemi A; Maleki M; Sadeghian S; Mohebbi B; Piazza G; Kirtane AJ; Lip GYH; Krumholz HM; Goldhaber SZ; Sadeghipour P
Thromb Res; 2020 Dec; 196():382-394. PubMed ID: 32992075
[TBL] [Abstract][Full Text] [Related]
4. Atorvastatin versus placebo in patients with covid-19 in intensive care: randomized controlled trial.
INSPIRATION-S Investigators
BMJ; 2022 Jan; 376():e068407. PubMed ID: 34996756
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial.
Spyropoulos AC; Goldin M; Giannis D; Diab W; Wang J; Khanijo S; Mignatti A; Gianos E; Cohen M; Sharifova G; Lund JM; Tafur A; Lewis PA; Cohoon KP; Rahman H; Sison CP; Lesser ML; Ochani K; Agrawal N; Hsia J; Anderson VE; Bonaca M; Halperin JL; Weitz JI;
JAMA Intern Med; 2021 Dec; 181(12):1612-1620. PubMed ID: 34617959
[TBL] [Abstract][Full Text] [Related]
6. Randomized clinical trial to evaluate a routine full anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) admitted to hospital: Rationale and design of the ACTION (AntiCoagulaTlon cOroNavirus)-Coalition IV trial.
Lopes RD; de Barros E Silva PGM; Furtado RHM; Macedo AVS; Ramacciotti E; Damini LP; Bronhara B; Cavalcanti AB; Rosa RG; Azevedo LCP; Veiga VC; Machado FR; Ritt LE; Martins PA; Alexander JH; Avezum A; Berwanger O;
Am Heart J; 2021 Aug; 238():1-11. PubMed ID: 33891907
[TBL] [Abstract][Full Text] [Related]
7. Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial.
Weitz JI; Bauersachs R; Becker B; Berkowitz SD; Freitas MCS; Lassen MR; Metzig C; Raskob GE
JAMA; 2020 Jan; 323(2):130-139. PubMed ID: 31935028
[TBL] [Abstract][Full Text] [Related]
8. Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients With COVID-19: COVID-PACT.
Bohula EA; Berg DD; Lopes MS; Connors JM; Babar I; Barnett CF; Chaudhry SP; Chopra A; Ginete W; Ieong MH; Katz JN; Kim EY; Kuder JF; Mazza E; McLean D; Mosier JM; Moskowitz A; Murphy SA; O'Donoghue ML; Park JG; Prasad R; Ruff CT; Shahrour MN; Sinha SS; Wiviott SD; Van Diepen S; Zainea M; Baird-Zars V; Sabatine MS; Morrow DA;
Circulation; 2022 Nov; 146(18):1344-1356. PubMed ID: 36036760
[TBL] [Abstract][Full Text] [Related]
9. Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-Critically Ill Hospitalized Patients With COVID-19: A Randomized Clinical Trial.
Berger JS; Kornblith LZ; Gong MN; Reynolds HR; Cushman M; Cheng Y; McVerry BJ; Kim KS; Lopes RD; Atassi B; Berry S; Bochicchio G; de Oliveira Antunes M; Farkouh ME; Greenstein Y; Hade EM; Hudock K; Hyzy R; Khatri P; Kindzelski A; Kirwan BA; Baumann Kreuziger L; Lawler PR; Leifer E; Lopez-Sendon Moreno J; Lopez-Sendon J; Luther JF; Nigro Maia L; Quigley J; Sherwin R; Wahid L; Wilson J; Hochman JS; Neal MD;
JAMA; 2022 Jan; 327(3):227-236. PubMed ID: 35040887
[TBL] [Abstract][Full Text] [Related]
10. Venovenous Extracorporeal Membrane Oxygenation With Prophylactic Subcutaneous Anticoagulation Only: An Observational Study in More Than 60 Patients.
Krueger K; Schmutz A; Zieger B; Kalbhenn J
Artif Organs; 2017 Feb; 41(2):186-192. PubMed ID: 27256966
[TBL] [Abstract][Full Text] [Related]
11. Effects of Standard-Dose Prophylactic, High-Dose Prophylactic, and Therapeutic Anticoagulation in Patients With Hypoxemic COVID-19 Pneumonia: The ANTICOVID Randomized Clinical Trial.
Labbé V; Contou D; Heming N; Megarbane B; Razazi K; Boissier F; Ait-Oufella H; Turpin M; Carreira S; Robert A; Monchi M; Souweine B; Preau S; Doyen D; Vivier E; Zucman N; Dres M; Fejjal M; Noel-Savina E; Bachir M; Jaffal K; Timsit JF; Picos SA; Mariotte E; Martis N; Juguet W; Melica G; Rondeau P; Audureau E; Mekontso Dessap A;
JAMA Intern Med; 2023 Jun; 183(6):520-531. PubMed ID: 36946232
[TBL] [Abstract][Full Text] [Related]
12. Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: A multi-center, open-label, randomized controlled trial.
Perepu US; Chambers I; Wahab A; Ten Eyck P; Wu C; Dayal S; Sutamtewagul G; Bailey SR; Rosenstein LJ; Lentz SR
J Thromb Haemost; 2021 Sep; 19(9):2225-2234. PubMed ID: 34236768
[TBL] [Abstract][Full Text] [Related]
13. Catheter-Directed Thrombolysis vs Anticoagulation in Patients With Acute Intermediate-High-risk Pulmonary Embolism: The CANARY Randomized Clinical Trial.
Sadeghipour P; Jenab Y; Moosavi J; Hosseini K; Mohebbi B; Hosseinsabet A; Chatterjee S; Pouraliakbar H; Shirani S; Shishehbor MH; Alizadehasl A; Farrashi M; Rezvani MA; Rafiee F; Jalali A; Rashedi S; Shafe O; Giri J; Monreal M; Jimenez D; Lang I; Maleki M; Goldhaber SZ; Krumholz HM; Piazza G; Bikdeli B
JAMA Cardiol; 2022 Dec; 7(12):1189-1197. PubMed ID: 36260302
[TBL] [Abstract][Full Text] [Related]
14. Deep vein thrombosis in hospitalized patients with coronavirus disease 2019.
Chang H; Rockman CB; Jacobowitz GR; Speranza G; Johnson WS; Horowitz JM; Garg K; Maldonado TS; Sadek M; Barfield ME
J Vasc Surg Venous Lymphat Disord; 2021 May; 9(3):597-604. PubMed ID: 33039545
[TBL] [Abstract][Full Text] [Related]
15. Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19.
Cosmi B; Giannella M; Fornaro G; Cristini F; Patacca A; Castagna A; Mazzaferri F; Testa S; Pan A; Lupi M; Brambilla P; Montineri A; Frattima S; Bignami EG; Salvetti M; De Stefano G; Grandone E; Di Perri G; Rozzini R; Stella A; Romagnoli A; Drago F; Viale P
BMC Infect Dis; 2023 Oct; 23(1):718. PubMed ID: 37875792
[TBL] [Abstract][Full Text] [Related]
16. Impact of High-Dose Prophylactic Anticoagulation in Critically Ill Patients With COVID-19 Pneumonia.
Tacquard C; Mansour A; Godon A; Godet J; Poissy J; Garrigue D; Kipnis E; Rym Hamada S; Mertes PM; Steib A; Ulliel-Roche M; Bouhemad B; Nguyen M; Reizine F; Gouin-Thibault I; Besse MC; Collercandy N; Mankikian S; Levy JH; Gruel Y; Albaladejo P; Susen S; Godier A;
Chest; 2021 Jun; 159(6):2417-2427. PubMed ID: 33465342
[TBL] [Abstract][Full Text] [Related]
17. Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial.
Connors JM; Brooks MM; Sciurba FC; Krishnan JA; Bledsoe JR; Kindzelski A; Baucom AL; Kirwan BA; Eng H; Martin D; Zaharris E; Everett B; Castro L; Shapiro NL; Lin JY; Hou PC; Pepine CJ; Handberg E; Haight DO; Wilson JW; Majercik S; Fu Z; Zhong Y; Venugopal V; Beach S; Wisniewski S; Ridker PM;
JAMA; 2021 Nov; 326(17):1703-1712. PubMed ID: 34633405
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial.
Sholzberg M; Tang GH; Rahhal H; AlHamzah M; Kreuziger LB; Áinle FN; Alomran F; Alayed K; Alsheef M; AlSumait F; Pompilio CE; Sperlich C; Tangri S; Tang T; Jaksa P; Suryanarayan D; Almarshoodi M; Castellucci LA; James PD; Lillicrap D; Carrier M; Beckett A; Colovos C; Jayakar J; Arsenault MP; Wu C; Doyon K; Andreou ER; Dounaevskaia V; Tseng EK; Lim G; Fralick M; Middeldorp S; Lee AYY; Zuo F; da Costa BR; Thorpe KE; Negri EM; Cushman M; Jüni P;
BMJ; 2021 Oct; 375():n2400. PubMed ID: 34649864
[TBL] [Abstract][Full Text] [Related]
19. Treatment-Dose LMWH versus Prophylactic/Intermediate Dose Heparins in High-Risk COVID-19 Inpatients: Rationale and Design of the HEP-COVID Trial.
Goldin M; Giannis D; Diab W; Wang J; Khanijo S; Sharifova G; Cohen M; Lund JM; Mignatti A; Gianos E; Tafur A; Lewis PA; Cohoon K; Kittelson JM; Lesser ML; Sison CP; Rahman H; Ochani K; Hiatt WR; Dale RA; Anderson VE; Bonaca M; Halperin JL; Weitz JI; Spyropoulos AC
Thromb Haemost; 2021 Dec; 121(12):1684-1695. PubMed ID: 33823560
[TBL] [Abstract][Full Text] [Related]
20. Durable functional limitation in patients with coronavirus disease-2019 admitted to intensive care and the effect of intermediate-dose vs standard-dose anticoagulation on functional outcomes.
INSPIRATION INVESTIGATORS
Eur J Intern Med; 2022 Sep; 103():76-83. PubMed ID: 35879217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
